July 19, 2017
JCR Pharmaceuticals and Teijin announced on July 18 that they have entered a codevelopment and license agreement for JTR-161, an allogeneic regenerative medicine product using dental pulp-derived stem cells (DPCs) for an indication of cerebral infarction in an acute phase...read more